Minerva Neurosciences to Host Webcast Event on Schizophrenia

Decision Resources Group to provide review of the disease landscape and forecast

Key opinion leader to discuss negative symptoms in schizophrenia

Minerva to outline roluperidone’s potential position within the disease landscape

WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA.

Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader.

Discussions will feature the following speakers and topics:

• Ryan Sowers, M.S. and Emma McFadden, Ph.D., Decision Resources Group: Schizophrenia: disease landscape and forecast
• Gregory P. Strauss, Ph.D., Assistant Professor; Director: Clinical Affective Neuroscience Laboratory; Director: Georgia Psychiatric Risk Evaluation Program; Department of Psychology, University of Georgia: The importance of negative symptoms in the treatment of schizophrenia
• Remy Luthringer, Ph.D., Executive Chairman and Chief Executive Officer, Minerva Neurosciences, Inc.: Roluperidone: Targeting the leading unmet need in schizophrenia

Institutional investors and analysts may RSVP to Mike Biega: mbiega@soleburytrout.com.

Interested parties may access the live video webcast of this presentation by visiting the Investors & Media section of Minerva’s website at www.minervaneurosciences.com. A webcast replay of the presentation will be posted on the Minerva website approximately two hours after the event and can be accessed at:  https://www.webcaster4.com/Webcast/Page/359/29852.

Decision Resources Group is not being compensated for their appearance and participation in this event.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva’s proprietary compounds include: roluperidone (MIN-101), in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and major depressive disorder (MDD); MIN-117, in Phase 2b clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com. 

Forward-Looking Safe Harbor Statement

This press release and webcast announced herein contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 12, 2019.  Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

Source: Minerva Neurosciences, Inc